Abstract-The protective effect of aliskiren, a direct renin inhibitor, against hypertensive cardiovascular and renal injury remains to be defined. This study was undertaken to examine the protective effects of the combination of aliskiren and valsartan, an angiotensin receptor blocker, against cardiovascular and renal injury. Endothelial NO synthase-deficient mice, subjected to cuff injury of femoral artery, were divided into 5 groups and were treated with the following: (1) vehicle; (2) aliskiren (25 mg/kg per day); (3) valsartan (8 mg/kg per day); (4) combined aliskiren (12.5 mg/kg per day) and valsartan (4 mg/kg per day); and (5) hydralazine (10 mg/kg per day) for 4 weeks. Aliskiren and valsartan alone markedly and similarly suppressed cardiac hypertrophy, inflammation and fibrosis, and coronary remodeling; prevented cuff injury-induced arterial intimal thickening; and reduced urinary albumin excretion, glomerular inflammation, and glomerulosclerosis in endothelial NO synthasedeficient mice. These beneficial effects of aliskiren and valsartan were associated with the significant attenuation of oxidative stress in these tissues. Hence, aliskiren and valsartan markedly exert the protective effects against cardiovascular and renal injury through the reduction of oxidative stress. Furthermore, compared with monotherapy with aliskiren or valsartan, the combination of a half dose of these drugs more greatly improved the above-mentioned cardiovascular and renal injuries of endothelial NO synthase-deficient mice, which were associated with greater attenuation of tissue oxidative stress by the combination therapy. Thus, the combination of aliskiren and valsartan exerts the synergistic organ-protective effects through synergistic attenuation of oxidative stress. The combination of aliskiren and valsartan seems to be a promising therapeutic strategy for hypertensive organ injury caused by endothelial NO synthase dysfunction. Key Words: eNOS Ⅲ oxidative stress Ⅲ combination therapy Ⅲ synergistic effect Ⅲ inflammation A ccumulating experimental and clinical evidence support the idea the renin-angiotensin system (RAS) plays a key role in the pathophysiology and development of hypertension, cardiac diseases, atherosclerosis, and renal diseases in a broad range of patients. 1 Mechanistically, conventional RAS blockers, angiotensin-converting enzyme inhibitor and angiotensin II type 1 (AT1) receptor blocker (ARB), attenuate feedback inhibition of renal renin release by suppressing the production and the action, respectively, of angiotensin II, which results in the increase in plasma renin activity. 1 Moreover, plasma renin activity is regarded as a risk factor for myocardial infarction in hypertensive patients. 2,3 Therefore, it is still unclear whether treatment with angiotensin-converting enzyme inhibitor or ARB allows optimized RAS suppression in patients with hypertension or cardiovascular and renal diseases.
A ccumulating experimental and clinical evidence support the idea the renin-angiotensin system (RAS) plays a key role in the pathophysiology and development of hypertension, cardiac diseases, atherosclerosis, and renal diseases in a broad range of patients. 1 Mechanistically, conventional RAS blockers, angiotensin-converting enzyme inhibitor and angiotensin II type 1 (AT1) receptor blocker (ARB), attenuate feedback inhibition of renal renin release by suppressing the production and the action, respectively, of angiotensin II, which results in the increase in plasma renin activity. 1 Moreover, plasma renin activity is regarded as a risk factor for myocardial infarction in hypertensive patients. 2, 3 Therefore, it is still unclear whether treatment with angiotensin-converting enzyme inhibitor or ARB allows optimized RAS suppression in patients with hypertension or cardiovascular and renal diseases.
Aliskiren is the first in a new class of orally effective direct renin inhibitors approved for the treatment of hypertension. 4 -6 In contrast to conventional RAS blockers, aliskiren blocks the renin system by directly inhibiting plasma renin activity and preventing the formation of both angiotensin I and angiotensin II, as shown by basic and clinical findings. 4 -6 However, it is unknown whether aliskiren is superior to conventional RAS blockers in terms of the prevention of cardiovascular and renal diseases.
Therefore, in the present study, to examine the protective effect of direct renin inhibition against hypertensive organ injury, we compared the effects of aliskiren, valsartan, and their combination on cardiovascular and renal injury of endothelial NO synthase (eNOS)-deficient mice with hypertension. We obtained evidence that the organ-protective effects of the combination of aliskiren and valsartan were greater than those of either monotherapy alone.
Methods

Animals and Drugs
Male eNOS
Ϫ/Ϫ mice 7, 8 and wild-type mice (C57BL/6J) were used for this study. All of the procedures were in accordance with institutional guidelines for animal research. Valsartan and aliskiren were kindly gifted from Novartis. Hydralazine was purchased from Sigma-Aldrich Co.
Effects of Aliskiren, Valsartan, and Their Combination on eNOS ؊/؊ Mice
This study was undertaken to compare the effect of each drug treatment on organ injury of eNOS Ϫ/Ϫ mice, under similar hypotensive effects. Therefore, in preliminary experiments, we examined the effects of various doses of aliskiren, valsartan, their combination, and hydralazine on blood pressure of eNOS Ϫ/Ϫ mice to determine the equihypotensive dose of each drug. Mice at the age of 12Ϯ2 weeks were used for this experiment. According to our previous method, 9 as described in the online Data Supplement (please see http://hyper.ahajournals.org.), we developed a model of vascular remodeling by placing a nonconstrictive polyethylene cuff (2-mm length, PE50, Becton Dickinson) loosely around the left femoral artery of eNOS Ϫ/Ϫ mice. eNOS Ϫ/Ϫ mice, subjected to the abovementioned cuff placement, were randomly assigned to 5 groups, including the following: (1) saline-infused group (control group); (2) hydralazine (10 mg/kg per day)-treated group; (3) valsartan (AT1 receptor blocker, 8 mg/kg per day)-treated group; (4) aliskiren (a direct renin inhibitor, 25 mg/kg per day)-treated group; and (5) combined valsartan (4 mg/kg per day) and aliskiren (12.5 mg/kg per day)-treated group. We chose the dose of 25 mg/kg per day for aliskiren monotherapy, because 25 mg/kg per day of aliskiren is the sufficient dose to sufficiently inhibit renin activity in mice in vivo. 10 Drug treatment was performed for 4 weeks. Valsartan, aliskiren, and saline (control) were given to mice via osmotic minipump (ALZA Co). Hydralazine was given to mice as the drinking water. Throughout the experiment, systolic blood pressure of the conscious mice was measured every week with the tail-cuff method (BP98A; Softron Co). After 4 weeks of the drug treatment, a 24-hour urine sample was collected from each mouse with metabolic cages. Then, mice were anesthetized with ether, and the heart, kidney, and cuff-injured femoral arteries were rapidly excised from each mouse to perform histological examination and to evaluate various biochemical and molecular parameters, as described in the online Data Supplement.
Results
Cardiovascular and Renal Phenotypes of eNOS ؊/؊ Mice
Blood pressure of eNOS Ϫ/Ϫ mice was significantly higher than that of wild-type mice (132Ϯ3 versus 101Ϯ2 mm Hg; PϽ0.01). Figure S1 (please see the online Data Supplement) shows the detail of phenotypes of eNOS Ϫ/Ϫ mice. Fifteenweek-old eNOS Ϫ/Ϫ mice displayed the enhancement of cardiac interstitial fibrosis, coronary arterial thickening, and cardiac macrophage infiltration compared with wild-type mice ( Figure S1A ). Intimal thickening of the femoral artery caused by cuff injury for 4 weeks was greater in eNOS Ϫ/Ϫ mice than in wild-type mice ( Figure S1B mice ( Figure S1C ). Moreover, superoxide levels in cardiac, injured arterial, and glomerular tissues were greater in eNOS Ϫ/Ϫ mice than in wild-type mice ( Figure S1 ). Thus, the phenotype of eNOS Ϫ/Ϫ mice was characterized not only by hypertension but also by cardiovascular and renal injuries and the enhancement of oxidative stress in these tissues.
Expression of AT1 Receptor mRNA and Protein in Cardiac and Renal Tissues of eNOS ؊/؊ Mice
As shown in Figure S2 , AT1a receptor mRNA levels in both cardiac and renal tissues were greater in eNOS Ϫ/Ϫ mice than in wild-type mice. Cardiac and renal AT1 receptor protein levels in eNOS Ϫ/Ϫ mice were also larger than those in wild-type mice.
Effect on Blood Pressure and Plasma Angiotensin II
Aliskiren (25 mg/kg per day) alone, valsartan (8 mg/kg per day) alone, the combination of a half-dose of aliskiren (12.5 mg/kg per day) and valsartan (4 mg/kg per day), and hydralazine significantly reduced blood pressure of eNOS Ϫ/Ϫ mice throughout the treatment ( Figure S3 ). There were no significant differences in the hypotensive effects among all of these drug treatments throughout the experiment. As shown in Figure S4 , plasma angiotensin II levels in eNOS Ϫ/Ϫ mice were markedly reduced by aliskiren monotherapy (PϽ0.01), whereas angiotensin II levels were significantly increased by valsartan monotherapy (PϽ0.01). Moreover, plasma angiotensin II concentrations in the combination group of valsartan plus aliskiren were lower than those in the valsartan monotherapy group (PϽ0.01) and the vehicle group (PϽ0.05). These results confirmed that aliskiren at the doses used in this study sufficiently inhibited plasma renin.
Effect on Cardiac Hypertrophy and Remodeling
As shown in Figure 1 , aliskiren or valsartan alone significantly and comparably reduced cardiac weight and cardiac interstitial fibrosis of eNOS Ϫ/Ϫ mice. On the other hand, hydralazine failed to reduce them. The combination of a half-dose of aliskiren and valsartan reduced cardiac weight and cardiac interstitial fibrosis more than monotherapy with either agent. As shown in Figure 2 , aliskiren and valsartan monotherapy, but not hydralazine, significantly and similarly reduced coronary arterial thickening and perivascular fibrosis of eNOS Ϫ/Ϫ mice. Furthermore, the combination of a halfdose of aliskiren and valsartan reduced these parameters more than either monotherapy. Figure 3 shows cardiac macrophage infiltration and cardiac superoxide levels of each group of eNOS Ϫ/Ϫ mice. In contrast to no effect of hydralazine on these parameters, valsartan and aliskiren monotherapy similarly and significantly reduced cardiac macrophage infiltration and superoxide levels of eNOS Ϫ/Ϫ mice. Moreover, their combination reduced cardiac macrophage infiltration and superoxide levels of eNOS Ϫ/Ϫ mice more than either monotherapy. receiving the combination of aliskiren and valsartan than in those subjected to either monotherapy. As shown in Figure 5 , the combination of aliskiren and valsartan reduced the number of proliferating cell nuclear antigen-positive cells in the intima and the media of the cuff-injured femoral artery more than either monotherapy. As shown in Figure 6 , aliskiren and valsartan, but not hydralazine, markedly attenuated superoxide in the intima and the media of the cuff-injured femoral artery of eNOS Ϫ/Ϫ mice. The combination of alikiren and valsartan reduced superoxide in both the intima and the media to a greater extent than either monotherapy alone.
Effect on Cuff Injury-Induced Arterial Intimal Hyperplasia
Effect on Renal Injury of eNOS ؊/؊ Mice
As shown in Figure 7 , valsartan or aliskiren monotherapy significantly reduced urinary albumin excretion, improved glomerulosclerosis index, reduced glomerular macrophage infiltration, and lessened glomerular superoxide levels of eNOS Ϫ/Ϫ mice, whereas hydralazine treatment failed to improve these parameters. The combination of aliskiren and valsartan improved all of these parameters more than either monotherapy.
Effect on Cardiac and Renal NADPH Oxidase Activities of eNOS ؊/؊ Mice
As shown in Figure 8 , cardiac and renal NADPH oxidase activities of eNOS Ϫ/Ϫ mice were significantly higher than those of wild-type mice. Valsartan and aliskiren monotherapies significantly and similarly reduced NADPH oxidase activity of both cardiac and renal tissues of eNOS Ϫ/Ϫ mice, whereas hydralazine did not significantly reduce it. Furthermore, the combination of these agents attenuated cardiac and renal NADPH oxidase activities more than either monotherapy alone.
Discussion
The major finding of our current study was that the combination of aliskiren and valsartan exerted greater organ-protective effects than monotherapy with a higher dose of either agent and was associated with greater attenuation of oxidative stress by the combination. Thus, our present work highlights the combination of aliskiren and valsartan as a promising therapeutic strategy for cardiovascular and renal diseases.
Accumulating clinical and experimental evidence indicates that eNOS, through NO production, plays a protective role not only in hypertension but also in cardiovascular and renal diseases. [11] [12] [13] [14] Importantly, essential hypertension is characterized by the defect of eNOS and the diminished NO production 14, 15 and is significantly associated with polymorphism in the eNOS gene. 16 Thus, it is a clinically very key issue whether RAS blockers protect against cardiovascular injury caused by eNOS dysfunction. In the current work, aliskiren and valsartan monotherapies both markedly prevented cardiac hypertrophy, inflammation and fibrosis, renal glomerulosclerosis and inflammation, and vascular intimal hyperplasia caused by cuff injury in eNOS-deficient mice, whereas the equihypotensive dose of hydralazine failed to prevent them. All of these findings show that these organ-protective effects of aliskiren and valsartan in eNOS-deficient mice were in part mediated by their direct inhibition of RAS independent of blood pressure, although the blood pressure-lowering effect might still be partially required for the protective effects of these agents.
Recent clinical data show the additive beneficial effects of the combination of aliskiren with conventional RAS blockers on patients with hypertension, 17 thy, 18 and heart failure. 19 However, importantly, in all of the previous clinical [17] [18] [19] and experimental 20 studies, the efficacy of combined aliskiren and ARB (or angiotensin-converting enzyme inhibitor) was compared with that of monotherapy with either agent at the same dose but not at a higher dose. Hence, it remains to be determined whether the combination of aliskiren with ARB is more effective than monotherapy with a higher dose of either agent. Therefore, in the present study, we compared the combination of aliskiren and valsartan with monotherapy with a double dose of either agent. The hypotensive effect of the combination of aliskiren and valsartan in eNOS-deficient mice was comparable to that of either monotherapy, providing no evidence for the superiority of the combination over a high dose of either monotherapy in terms of blood pressure-lowering effects. However, of note, the combination of aliskiren and valsartan suppressed cardiac hypertrophy, inflammation and fibrosis, coronary arterial remodeling, cuff injury-induced femoral arterial intimal thickening, renal glomerulosclerosis, and inflammation of eNOS-deficient mice to a greater extent than either monotherapy alone. These findings provide the first evidence that the combination of aliskiren and valsartan exerts greater organ-protective effects than monotherapy with higher dose of either agent alone.
Oxidative stress is involved in the onset and development of cardiovascular and renal diseases. [21] [22] [23] [24] NO plays antiatherogenic role by counteracting oxidative stress. 11, 21, 25 In the present study, as expected, we found the enhancement of superoxide, the initial product of reactive oxygen species, in the heart, the kidney, and cuff-injured femoral artery of eNOS-deficient mice ( Figure S1 ), supporting the contribution of oxidative stress to organ injuries in eNOS-deficient mice. Notably, the combination of aliskiren and valsartan exerted more attenuation of cardiac, arterial, and renal superoxide in eNOS-deficient mice than either monotherapy alone ( Figures  3, 6 , and 7), which was attributed to greater suppression of NADPH oxidase activity by the combination therapy ( Figure  8 ). These findings show that greater organ-protective effects of the combination therapy in eNOS-deficient mice than either monotherapy are at least in part attributed to more attenuation of NADPH oxidase-mediated oxidative stress by the combination therapy.
Study Limitation
Importantly, hypertensive patients and animals are characterized by partial attenuation of eNOS, differing from complete absence of eNOS in eNOS-deficient mice. Therefore, much caution should be given regarding the interpretation and the implication of our current results obtained from eNOSdeficient mice (a particular hypertensive model). The mechanisms underlying vascular protection of aliskiren and ARBs in hypertensive animals or patients are partially mediated by the improvement of eNOS function, such as the enhancement of eNOS activity and the inhibition of eNOS uncoupling. 11,20,26 -28 Thus, the use of eNOS-deficient mice in this work did not allow us to examine the potential of the eNOS-mediated benefit of the combination of these agents. Additional study using other hypertensive models is needed to confirm the benefits of their combination therapy.
In conclusion, we obtained evidence that the combination of aliskiren and valsartan exerted greater protective effects against cardiovascular and renal diseases caused by eNOS deficiency than monotherapy with a double dose of either agent through greater attenuation of tissue oxidative stress.
Perspectives
Risk factors, such as hypertension, diabetes mellitus, or dyslipidemia, are significantly associated with eNOS dysfunction. Our current experimental findings highlight the combination therapy of aliskiren with valsartan as the promising therapeutic strategy for cardiovascular and renal diseases.
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Online method Animals and drugs
Male eNOS-/-mice 1, 2 and wild-type mice (C57BL/6J) were used for this study. All procedures were in accordance with institutional guidelines for animal research. Valsartan and aliskiren were kindly gifted from Novartis (Basel, Switzerland). Hydralazine was purchased from Sigma-Aldrich Co. (Missouri, USA) .
Effect of aliskiren, valsartan and their combination on eNOS-/-mice
This study was undertaken to compare the effect of each drug treatment on organ injury of eNOS-/-mice, under similar hypotensive effects. Therefore, in preliminary experiments, we examined the effect of various doses of aliskiren, valsartan, their combination, and hydralazine on blood pressure of eNOS-/-mice, to determine the equihypotensive dose of each drug. Mice at the age of 12±2 weeks were used for this experiment. According to our previous method, 3 as described later, we developed a model of vascular remodeling by placing a non constructive-polyethylene cuff (2 mm length, PE50; Becton Dickinson, Mountain View, CA, USA) loosely around left femoral artery of eNOS-/-mice. eNOS-/-mice, subjected to the above mentioned cuff placement, were randomly assigned to 5 groups, including (1) saline-infused group (control group), (2) hydralazine (10 mg/kg/day)-treated group, (3) valsartan (AT1 receptor blocker, 8 mg/kg/day)-treated group, (4) aliskiren (a direct renin inhibitor, 25 mg/kg/day)-treated group, and (5) combined valsartan (4 mg/kg/day) and aliskiren (12.5 mg/kg/day)-treated group. Previous report 4 indicates that the administration of 25 mg/kg/day of aliskiren in mice sufficiently inhibits plasma renin in vivo. As the main purpose of our work was to examine the efficacy of renin inhibition with aliskiren on cardiovascular and renal diseases, it was appropriate to use the dose of aliskiren enough to inhibit plasma renin in vivo. Therefore, in this work, we used the above mentioned hypotensive doses of aliskiren and valsartan. Drug treatment was performed for 4 weeks. Valsartan, aliskiren, and saline (control) were given to mice via osmotic minipump (ALZA Co., California, USA). Hydralazine was given to mice as the drinking water. Throughout the experiment, systolic blood pressure of the conscious mice was measured every week with the tail-cuff method (BP98A; Softron Co). After 4 weeks of the drug treatment, 24 hour-urine sample was collected from each mouse with metabolic cages. Then, mice were anesthetized with ether, and the heart, kidney, and cuff-injured femoral arteries were rapidly excised from each mouse to perform histological examination and to evaluate various biochemical and molecular parameters, as described in Online Supplement.
Periadventitial vascular injury prodecure
The surgical procedure for cuff-induced periadventitial injury was performed, according to the method previously described with some modification 3 . In brief, mice were anesthesized with pentobarbital by intraperitoneal injection. The right and left femoral arteries of the mice were dissected from the surrounding tissue. A non constructive-polyethylene cuff (2 mm length, PE50; Becton Dickinson, Mountain View, CA, USA) was placed loosely around the left femoral artery.
Morphometry and cell proliferation of cuff-injured arteries
Paraffin-embedded sections were used for morphometry and proliferating cell analysis of cuff-injured femoral arteries, as described 3 . The harvested injured arteries were cut into cross sections and were stained with Elastica Van Gieson. For each artery section, the areas of the intima, media, and lumen were measured utilizing image-analysis software (Lumina Vision). Three cross-section cuts, at least 250 μm intervals, were obtained from each artery, and then the measurements of the sections from each animal were averaged for morphometrical analysis.
For proliferating cell nuclear antigen (PCNA) staining, we used PCNA staining kit (ZYMED Laboratories, San Francisco, CA, USA), and counter-stained with methylgreen (WAKO Co. Ltd., Osaka, Japan).
Histological examination on cardiac and renal tissues
The heart and kidney from each mouse were fixed in 4 % paraformaldehyde overnight and embedded in paraffin. Cardiac sections (5 µm thick) were stained with Sirius Red F3BA (0.5 % in saturated aqueous picric acid, Aldrich Chemical Company) for assessment of cardiac interstitial fibrosis and coronary remodeling. To evaluate coronary remodeling, coronary arterial thickening was assessed by calculating the wall-to-lumen ratio (the medial thickness to the internal diameter), as previously described 5 . The area of perivascular fibrosis per vessel was assessed by using image-analysis software (Lumina Vision version 2.2, Mitani Co., Fukui, Japan; Image J, National Institutes of Health, Bethesda, Maryland, USA).
Renal sections (5 μm thick) were stained with hematoxylineosin and periodic acid-Schiff (PAS) and were analyzed for degree of glomerulosclerosis, defined as disappearance of cellular elements from the tuft, capillary loop collapse, folding of the glomerular basement membrane with accumulation of amorphous material, as described 6 . The grades were 0, 0 %; I, 1 to 25 %; II, 26 % to 50 %; III, 51 to 75 %; and IV, 76 % to 100 % of glomeruli involved. The glomerurosclerosis score was calculated as (1 x % grade I) + (2 x % grade II) + (3 x % grade III) + (4 x % grade IV). One hundred glomeruli were examined from each animal.
Measurement of cardiac and glomerular macrophage infiltration.
Cardiac and renal tissues, removed from mice, were immediately frozen in Tissue-Tek O.C.T. embedding medium (Sakura Finetek). For detection of macrophage infiltration, the frozen sections were stained with the primary antibodies (rat anti-mouse CD68, Serotec; x500) at 4°C overnight 7 . After incubation with the primary antibodies, HRP conjugated anti-rat IgG secondary antibody (BioSource, Camarillo, CA, USA) was utilized. The reactions were visualized with 3,3'-diaminobenzidine (DakoCytomation, Carpinteria, CA, USA), and counter-stained with hematoxylin. Negative controls were prepared by substitution of the primary antibody with an irrelevant antibody.
Measurement of tissue superoxide
Dihydroethidium (DHE) was used to evaluate tissue superoxide levels in situ, as described previously 8 . DHE fluorescence of cardiac, renal and femoral arterial sections was quantified using image-analysis software (Lumina Vision). The mean fluorescence was quantified and expressed relative to values obtained from vehicle saline-treated eNOS-/-mice.
Measurement of NADPH oxidative activity
The heart and the kidney were homogenized with a POLYTRON homogenizer PT1200E (KINEMATICA AG), centrifuged, and cardiac NADPH oxidase activity of the resulting supernatant was measured by lucigenin chemiluminescence in the presence of modified Krebs/HEPES buffer (pH 7.4) equilibrated at 37°C, 10 μM NADPH, and 10 μM lucigenin as electron acceptor, as described previously 8 . The chemiluminescence was then recorded every 15 seconds for 5 minutes, with the use of a luminescence reader (BLR-201, Aloka). Values of chemiluminescence were expressed as cpm/mg protein. Protein concentrations were measured by the method of Bradford.
Preparation of cardiac and renal protein extracts and Western blot analysis
Our detailed method has been described previously. As primary antibodies, anti-AT1 receptor antibody (x2000, Santa Cruz) and anti-α-tubulin (x5000, Oncogene) were used. The antibody was visualized using an enhanced chemiluminescence method (ECL Plus; Amersham Biosciences). The intensity of the bands was quantified using NIH Image analysis software v1.61. In individual samples, each value was corrected for that of α-tubulin.
Real-time quantitative reverse transcriptase-polymerase chain reaction
Total RNA was isolated from left ventricle and kidney samples (30 mg each) using Isogen (Nippon Gene, Tokyo, Japan). Complementary DNAs were synthesized by reverse transcription of 1µg total RNA according to the QuantiTect Reverse Transcription Handbook (QIAGEN Inc., Hilden, Germany). Real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was carried out to evaluate the expression levels of angiotensin type 1a (AT1a) receptor, by using Thermal Cycler Dice Real Time System (Takara Biochemicals, Kyoto, Japan). The following sets of primers were used for PCR; AT1a receptor; forward, 5′-GGACACTGCCATGCCCATAAC -3′; reverse, 5′ -TGAGTGCGACTTGGCCTTTG-3′. SyBr Green assays were performed with the qPCR Master Mix for SYBR Green I (Takara). Specificity of the SyBr Green assays was confirmed by melting point analysis. mRNA for the housekeeping gene glyceraldehyde-3-phosphatedehydrogenase (GAPDH) (Applied Biosystems, California, U.S.A.) was also quantitated for normalization, since GAPDH is regarded as a useful internal control for mRNA quantification. Ct value and relatively calculated by setting a calibrator sample in each run using standard curve method.
Measurement of urinary albumin excretion
The mice were housed in metabolic cages for 24-hour to collect urine. Urinary albumin excretion was measured by using a mouse Albumin ELISA Quantitation kit (albuwell, Exocell, Philadelphia, USA), according to the manufacturer's instruction.
Measurement of plasma angiotensin II
Angiotensin II concentrations were measured in plasma from 5 experimental groups of eNOS-/-mice subjected to cuff injury and treated with each drug for 4 weeks and from wild type mice subjected to cuff injury in the same manner as eNOS-/-mice. The measurement of angiotensin II in plasma was carried out by high performance liquid chromatography coupled with a specific radioimmunoassay, according to our established method previously described in detail.
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Statistical Analysis
All data are presented as mean±SEM. Comparison between 2 groups was analyzed by unpaired Student's t-test using Prism (GraphPad Software Inc., San Diego, CA, USA). In comparison among more than 2 groups, statistical significance was determined with one-way ANOVA, followed by Fisher's PLSD test. In all tests, differences were considered statistically significant at a value of P<0.05. 
